Reply: Comment on 'KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colo-rectal cancer'.
作者信息
Renaud Stéphane, Falcoz Pierre-Emmanuel, Romain Benoit, Olland Anne, Santelmo Nicola, Brigand Cécile, Rohr Serge, Guenot Dominique, Massard Gilbert
机构信息
Department of Thoracic Surgery, Strasbourg University Hospital, Strasbourg, France.
Research unit EA3430: Tumoral Progression and Micro-environnement, Translational and Epidimiological Approachs, Strasbourg University, Strasbourg, France.
出版信息
Br J Cancer. 2015 Dec 1;113(11):1637-8. doi: 10.1038/bjc.2015.330. Epub 2015 Sep 15.
Abstract
摘要
相似文献
1
Reply: Comment on 'KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colo-rectal cancer'.
Br J Cancer. 2015 Dec 1;113(11):1637-8. doi: 10.1038/bjc.2015.330. Epub 2015 Sep 15.
2
Comment on: 'KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer.' Variation in survival associated with proto-oncongenes is not evidence for effectiveness of lung metastasectomy.
Br J Cancer. 2015 Dec 1;113(11):1636. doi: 10.1038/bjc.2015.331. Epub 2015 Sep 15.
3
KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer.
Br J Cancer. 2015 Feb 17;112(4):720-8. doi: 10.1038/bjc.2014.499.
4
EGFR, BRAF and KRAS status in patients undergoing pulmonary metastasectomy from primary colorectal carcinoma: a prospective follow-up study.
Ann Surg Oncol. 2014 Mar;21(3):946-54. doi: 10.1245/s10434-013-3386-7. Epub 2013 Nov 27.
5
BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy.
J Surg Oncol. 2012 Aug 1;106(2):123-9. doi: 10.1002/jso.23063. Epub 2012 Feb 13.
6
How can we identify new biomarkers for patients with for lung metastasectomy in colorectal cancer.
Future Oncol. 2015;11(15):2109-11. doi: 10.2217/fon.15.124.
7
[Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
Zhonghua Bing Li Xue Za Zhi. 2014 Feb;43(2):77-82.
8
KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.
Ann Surg Oncol. 2010 May;17(5):1429-34. doi: 10.1245/s10434-009-0864-z. Epub 2010 Jan 5.
9
Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.
J Hepatobiliary Pancreat Sci. 2013 Feb;20(2):223-33. doi: 10.1007/s00534-012-0531-9.
10
EGFR fluorescence in situ hybridization-positive lung adenocarcinoma: incidence of coexisting KRAS and BRAF mutations.
Hum Pathol. 2010 Aug;41(8):1053-60. doi: 10.1016/j.humpath.2010.01.008. Epub 2010 Apr 8.
本文引用的文献
1
Comment on: 'KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer.' Variation in survival associated with proto-oncongenes is not evidence for effectiveness of lung metastasectomy.
Br J Cancer. 2015 Dec 1;113(11):1636. doi: 10.1038/bjc.2015.331. Epub 2015 Sep 15.
2
The Impact of Colleague Peer Review on the Radiotherapy Treatment Planning Process in the Radical Treatment of Lung Cancer.
Clin Oncol (R Coll Radiol). 2015 Sep;27(9):514-8. doi: 10.1016/j.clon.2015.05.010. Epub 2015 Jul 3.
3
Radiofrequency ablation of stage IA non-small cell lung cancer in medically inoperable patients: Results from the American College of Surgeons Oncology Group Z4033 (Alliance) trial.
Cancer. 2015 Oct 1;121(19):3491-8. doi: 10.1002/cncr.29507. Epub 2015 Jun 19.
4
Stereotactic Ablative Radiation Therapy for the Treatment of Early-stage Non-Small-Cell Lung Cancer: CEPO Review and Recommendations.
J Thorac Oncol. 2015 Jun;10(6):872-82. doi: 10.1097/JTO.0000000000000524.
5
KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer.
Br J Cancer. 2015 Feb 17;112(4):720-8. doi: 10.1038/bjc.2014.499.
6
Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model.
FASEB J. 2015 Feb;29(2):464-76. doi: 10.1096/fj.14-262303. Epub 2014 Oct 30.
7
KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma.
J Thorac Oncol. 2014 Oct;9(10):1513-22. doi: 10.1097/JTO.0000000000000305.
8
The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma.
J Thorac Oncol. 2014 Sep;9(9):1363-9. doi: 10.1097/JTO.0000000000000266.
9
CEA monitoring in colorectal cancer is not a waste of time.
BMJ. 2014 Jun 18;348:g4032. doi: 10.1136/bmj.g4032.
10
The CEA Second-Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer.
BMJ Open. 2014 May 13;4(5):e004385. doi: 10.1136/bmjopen-2013-004385.
Zotero 插件